MedTrace Logo

Expanded Access to Navitoclax

NCT03592576 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-05-06

No results posted yet for this study

Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Conditions

  • Myelofibrosis
  • Acute Lymphocytic Leukemia (ALL)
  • Lymphoblastic Lymphoma

Interventions

DRUG

Navitoclax

Tablet, Oral

DRUG

Venetoclax

Tablet, Oral

Sponsors & Collaborators

Eligibility

Min Age
4 Years
Sex
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03592576 on ClinicalTrials.gov